GU Cancers 2021 | Emerging treatment options for patients with prostate cancer
Jana McHugh, MD, of The Institute of Cancer Research, London, UK, discusses exciting new treatment options for prostate cancer, such as PARP inhibitors for patients with BRCA1 & 2 mutations and radionuclide therapy with prostate-specific membrane antigen (PSMA)-targeted radiation. Dr McHugh goes on to describe how the advent of hypofractionation is especially impactful during the COVID-19 pandemic as patients are likely to have less frequent hospital visits. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Dr Jana McHugh, MD, has received institutional research grants from the European Research Council, the NIRH Biomedical Research Centre at the Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research.
